Umpierrez G, et al. - In patients with type 2 diabetes, researchers examined how dulaglutide influences the comparative contribution of basal hyperglycemia (BHG) and postprandial hyperglycemia (PPHG) to overall hyperglycemia over HbA1c categories. As per pooled data from five phase 3 studies (N = 673), 6 months of treatment intensification with dulaglutide 1.5 mg leads to a significant decrease in overall hyperglycemia, BHG, and PPHG from baseline. Results thereby indicate that, over a range of HbA1c categories, dulaglutide lowers both BHG and PPHG to reduce HbA1c in patients with type 2 diabetes. Relative contributions of BHG increased and PPHG decreased with increasing HbA1c levels at baseline.